Stock 2696 SHANGHAI HENLIUS BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Revisions Shanghai Henlius Biotech, Inc.

Equities

2696

CNE100003N76

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:22 2024-05-10 am EDT 		5-day change 1st Jan Change
17.2 HKD +1.42% Intraday chart for Shanghai Henlius Biotech, Inc. +2.99% +23.74%
May. 06 Henlius Biotech Gets US FDA Clearance for Phase 3 Trial of Gastric Cancer Combination Therapy MT
May. 06 Shanghai Henlius Biotech, Inc. Announces Application for the Phase 3 Clinical Trial of HLX22 in Combination with Trastuzumab and Chemotherapy as the First-Line Treatment of HER2 Positive Advanced Gastric Cancer Approved by the United States Food and Drug Administration CI

Turnover - Change in analysts' estimates

Earnings Per Share (EPS) - Change in analysts' estimates

EBIT - Change in analysts' estimates

Turnover

Earnings Per Share (EPS)

EBIT

  1. Stock Market
  2. Equities
  3. 2696 Stock
  4. Revisions Shanghai Henlius Biotech, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW